The Ankylosing Spondylitis Market to Surge at a Significant CAGR of 5.4% by 2032, Estimates DelveInsight

The Ankylosing Spondylitis market size is anticipated to increase during the forecast period owing to the launch of several new products with novel mechanisms of action for Ankylosing Spondylitis treatment, including anti-IL17A, JAK inhibitors, and biologics. Moreover, private and government organizations have taken certain initiatives to raise awareness about the disease. Last year, the Spondylitis Association of America (SAA) officially celebrated SpA Awareness. 

LAS VEGAS, May 9, 2022 /PRNewswire/ -- DelveInsight's Ankylosing Spondylitis Market Insights report includes a comprehensive understanding of current treatment practices, Ankylosing Spondylitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 , and Japan.

DelveInsight_Logo

Key Takeaways from the Ankylosing Spondylitis Market Report

  • According to DelveInsight, the Ankylosing Spondylitis market size in the 7MM was around USD 4,200 million in 2021.
  • As per the analysis, the total Ankylosing Spondylitis prevalent population in 7MM was around 2.2 million in 2021. 
  • Leading Ankylosing Spondylitis companies UCB, AbbVie, Astellas, Amgen, Pfizer, Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, Celgene, Inmagene Biopharmaceuticals, and others are currently dominating the Ankylosing Spondylitis market.
  • The Ankylosing Spondylitis therapies in the pipeline include Bimekizumab, CC-99677, ABY- 035, and others.
  • The Ankylosing Spondylitis market is expected to grow by factors like an increase in the prevalent patient and the expected entry of emerging therapies into the Ankylosing Spondylitis market. 

Discover more about therapies set to grab major Ankylosing Spondylitis market share at Ankylosing Spondylitis Market Landscape

Ankylosing Spondylitis Overview

Ankylosing Spondylitis, commonly known as Bechterew's disease, is a common inflammatory rheumatic disease that affects the axial skeleton.  Ankylosing Spondylitis causes typical inflammatory back pain, which can lead to structural and functional deficits as well as a decline in quality of life. Genetics plays an important role in ankylosing spondylitis occurrence, over 90% of patients with this condition have a particular genetic marker in their white blood cells, called HLA-B27. The HLA-B27 Ankylosing Spondylitis genetic marker appears to play a role in over 90% of the cases. The primary Ankylosing Spondylitis risk factors responsible for the development of the disease are age, gender, other genes, and heredity. Ankylosing Spondylitis life expectancy can be considered somewhat similar to that of the general population if the non-serious form of the disease is present, on the contrary patients who have the most severe forms of the disease can experience serious complications.

Early Ankylosing Spondylitis symptoms may include discomfort and stiffness in the lower back and hips, particularly in the morning and after periods of inactivity. Neck pain and fatigue are also prevalent. Signs of Ankylosing Spondylitis may intensify, improve, or cease at unpredictable periods throughout time.

Ankylosing Spondylitis diagnosis criteria might be challenging because the disorder progresses slowly and there is no definitive Ankylosing Spondylitis test. For Ankylosing Spondylitis, the modified New York classification is now utilized for both research and therapeutic purposes. Physical exam, individual medical history, and a family history of Ankylosing Spondylitis, as well as blood tests (including a test for HLA-B27), are factors responsible for Ankylosing Spondylitis diagnosis. Ankylosing Spondylitis x-ray is also an important tool for diagnosis.

Ankylosing Spondylitis Epidemiology Segmentation

As per DelveInsight, there was around 2.2 million Ankylosing Spondylitis prevalent population in the 7MM in 2021.

Among EU5 countries, Germany had the highest Ankylosing Spondylitis prevalence in 2021.

The Ankylosing Spondylitis Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

  • Total Prevalent cases of Ankylosing Spondylitis 
  • Diagnosed Prevalent Cases of Ankylosing Spondylitis 
  • Gender-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis
  • Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis
  • Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis 

Download the report to understand which factors are driving Ankylosing Spondylitis epidemiology trends at Ankylosing Spondylitis Epidemiological Insights

Ankylosing Spondylitis Treatment Market

There is no Ankylosing Spondylitis cure, however, therapies can alleviate Ankylosing Spondylitis symptoms and perhaps delay disease development. Recent research indicates that newer biologics for Ankylosing Spondylitis may be able to delay disease development in certain patients. Different people respond to different Ankylosing Spondylitis medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment for Ankylosing Spondylitis.

Ankylosing Spondylitis medications include Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Corticosteroids, Biologics, TNF Inhibitors, Interleukin Inhibitors, and pain medications.

Medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain are common Ankylosing Spondylitis treatment regimens for the various forms of spondyloarthritis. In extreme situations, posture-correction surgery may be considered. Ankylosing Spondylitis treatment options may differ depending on the kind of spondyloarthritis. In the case of psoriatic arthritis, for example, both the skin and the joint components must be addressed. Ankylosing Spondylitis medications may need to be changed in enteropathic arthritis (spondylitis/arthritis linked with inflammatory bowel disease) so that the gastrointestinal component of the disease is also addressed and not aggravated.

Furthermore, Ankylosing Spondylitis pipeline includes prospective monotherapies as well as combo treatments. Overall, the Ankylosing Spondylitis market is likely to grow further over the forecast period (2022–2032).

To know about more Ankylosing Spondylitis medications visit at Ankylosing Spondylitis Treatment 

Ankylosing Spondylitis Pipeline Therapies and Key Companies

  • Bimekizumab: UCB Biopharma
  • CC-99677: Celgene
  • ABY- 035: Inmagene Biopharmaceuticals

Ankylosing Spondylitis Market Dynamics

Certain efforts, such as Ankylosing Spondylitis Awareness Month in May, have been implemented by corporate and public sector groups to promote awareness of the condition. These initiatives will impact the growth of the Ankylosing Spondylitis market. In addition, pharmaceutical companies have increased their investments in drug research and development, thereby driving the Ankylosing Spondylitis market growth. Furthermore, newer, more novel therapies have been discovered to break the inflammatory cycle in Ankylosing Spondylitis by selectively targeting cytokines that cause inflammation, such as IL17A, thus, impacting the Ankylosing Spondylitis market positively. Moreover, the increase in Ankylosing Spondylitis prevalence will also create a lucrative opportunity for the Ankylosing Spondylitis market.

However, there is still an unmet need to identify individuals who may safely cease therapy. In addition, tumor necrosis factor inhibitor (TNFi) is a primary pharmacologic therapy that most people do not react to. These are among the major factors acting as a barrier to the Ankylosing Spondylitis market. Moreover, many years pass between the onset of symptoms and the diagnosis, and over-diagnosis is prevalent, thereby impeding the growth of the Ankylosing Spondylitis market. 

Furthermore, the introduction of biosimilars into the Ankylosing Spondylitis market will raise competition and may stymie the Ankylosing Spondylitis market for both approved and future drugs if they are shown to be more effective and promising. It has also been noticed that enhanced regulatory systems are permitting and simplifying the approval of biosimilars. The approval of biosimilars will result in a decrease in sales, illustrating the rising possibility of significant income loss following the patent expiration of already approved drugs.

Scope of the Ankylosing Spondylitis Market Report

  • Study Period: 2019-2032
  • Coverage: 7MM [The United States, EU5 , and Japan]
  • Key Ankylosing Spondylitis Companies: UCB, AbbVie, Astellas, Amgen, Pfizer, Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, Celgene, Inmagene Biopharmaceuticals, and others
  • Key Ankylosing Spondylitis Therapies: Bimekizumab, CC-99677, ABY- 035, and others
  • Therapeutic Assessment: Ankylosing Spondylitis current marketed and emerging therapies
  • Ankylosing Spondylitis Market Dynamics:  Ankylosing Spondylitis market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Ankylosing Spondylitis Market Access and Reimbursement

Discover more about the future Ankylosing Spondylitis market share of treatment therapies at New Drugs for Ankylosing Spondylitis 

Table of Contents

1.

Ankylosing Spondylitis Market Key Insights

2.

Ankylosing Spondylitis Market Report Introduction

3.

Ankylosing Spondylitis Market Overview at a Glance

4.

Ankylosing Spondylitis Market Executive Summary

5.

Disease Background and Overview

6.

Ankylosing Spondylitis Treatment and Management

7.

Ankylosing Spondylitis Epidemiology and Patient Population

8.

Patient Journey

9.

Ankylosing Spondylitis Marketed Drugs

10.

Ankylosing Spondylitis Emerging Drugs

11.

7 Major Ankylosing Spondylitis Market Analysis

12.

Ankylosing Spondylitis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Ankylosing Spondylitis Market Drivers

16

Ankylosing Spondylitis Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Get in touch with our Business executive at Healthcare Due Diligence Services 

Related Reports

Ankylosing Spondylitis Epidemiology

Ankylosing Spondylitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Ankylosing Spondylitis epidemiology in the 7MM.

Ankylosing Spondylitis Pipeline

Ankylosing Spondylitis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ankylosing Spondylitis companies involved such as Fresenius Kabi, Shanghai Henlius Biotech, Pfizer, among others.

Ankylosing Spondylitis Market 

Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ankylosing Spondylitis companies such as Pfizer, UCB Biopharma, among others.

Axial Spondyloarthritis Market

Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Axial Spondyloarthritis companies such as Eli Lilly and Company, Kyowa Kirin, AbbVie, among others.

Axial Spondyloarthritis Epidemiology

Axial Spondyloarthritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Axial Spondyloarthritis epidemiology in the 7MM.

Axial Spondyloarthritis Pipeline

Axial Spondyloarthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Axial Spondyloarthritis companies involved such as Izana Bioscience, Kyowa Kirin Co. Ltd., Luye Pharma Group, among others.

Other Trending Reports

Diabetes Market

The Diabetes Market report delivers an in-depth understanding of the Diabetes, historical and forecasted epidemiology as well as the Diabetes market size and shares in the 7MM. Some of the key companies in the Diabetes Market include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and Others.

Type 2 Diabetes Market

The Type 2 Diabetes Market research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Type 2 Diabetes market size, share, and trends in the 7MM. Some of the key companies in the Type 2 Diabetes Market include Bayer, Eli Lilly and Company, Oramed and AstraZeneca, and Others.

Small Cell Lung Cancer Market

The Small Cell Lung Cancer (SCLC) Market report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market size, share, and trends in 7MM. Some of the key companies in the Small Cell Lung Cancer Market include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others.

Follicular Lymphoma Market

The Follicular Lymphoma Market research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Follicular Lymphoma market size, share, and trends in the 7MM. Some of the key companies in the Follicular Lymphoma Market include Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.

Fragile X Syndrome (FXS) Market

The Fragile X Syndrome (FXS) Market report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market size, share, and trends in the 7MM. Some of the key companies in the Fragile X Syndrome (FXS) Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, and others.

Related Healthcare Blogs

Ankylosing Spondylitis Treatment Market

Key Drugs in Pipeline for Autoimmune Diseases 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedInFacebookTwitter

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Cision View original content:https://www.prnewswire.com/news-releases/the-ankylosing-spondylitis-market-to-surge-at-a-significant-cagr-of-5-4-by-2032--estimates-delveinsight-301542443.html

SOURCE DelveInsight Business Research, LLP

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.